Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Appetite suppressants. A review.

T Silverstone1

  • 1Medical College, St Bartholomew's Hospital, University of London, England.

Drugs
|June 1, 1992
PubMed
Summary
This summary is machine-generated.

Appetite suppressants, targeting catecholamine or serotonin pathways, aid weight loss in obesity. Dexfenfluramine shows promise, but use requires careful patient selection and comprehensive weight management.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Drugs and driving.

British journal of clinical pharmacology·2012
Same author

Menstrual cycle effects on the action of buspirone on food intake in healthy female volunteers.

Journal of psychopharmacology (Oxford, England)·2012
Same author

A double-blind placebo-controlled study of rolipram in depressed in-patients.

Journal of psychopharmacology (Oxford, England)·2012
Same author

Neurochemical and psychoanalytical approaches to mania.

Proceedings of the Royal Society of Medicine·2010
Same author

Sumatriptan challenge in bipolar patients with and without migraine: a neuroendocrine study of 5-HT1D receptor function.

International clinical psychopharmacology·2002
Same author

Serotonin and bipolar disorder.

Journal of affective disorders·2001
Same journal

Ecnoglutide: First Approvals.

Drugs·2026
Same journal

The Long Road to Long-Acting: What Oral PrEP and CAB-LA Teach Us About Scaling Lenacapavir.

Drugs·2026
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
See all related articles

Area of Science:

  • Pharmacology
  • Obesity Treatment
  • Neuroscience

Background:

  • Obesity is a significant health concern requiring effective management strategies.
  • Centrally acting appetite suppressants are a key therapeutic option.
  • These drugs operate via two main pharmacological pathways: catecholamine and serotonin.

Purpose of the Study:

  • To review the pharmacological categories of appetite suppressants.
  • To evaluate their efficacy and safety in obesity treatment.
  • To identify the most suitable pharmacological profiles for long-term use.

Main Methods:

  • Review of existing literature on appetite suppressant drugs.
  • Categorization based on primary neurotransmitter pathways (catecholamine vs. serotonin).

Related Experiment Videos

  • Analysis of clinical trial data regarding efficacy, safety, and duration of use.

    • Main Results:

    • Catecholamine pathway drugs (e.g., phentermine) have stimulant/sympathomimetic properties; some are no longer recommended due to risks.
    • Serotonin pathway drugs (e.g., dexfenfluramine, fluoxetine) lack stimulant properties and are effective.
    • Dexfenfluramine exhibits a favorable profile but is contraindicated in patients with depression.

    Conclusions:

    • Appetite suppressants can be beneficial for clinically at-risk overweight individuals as part of a comprehensive program.
    • While short-term use is regulated, evidence supports longer-term efficacy, especially for weight regain prevention.
    • Appropriate use of appetite suppressants offers therapeutic benefits with minimal risk.